Real-time enrollment status for this post-transplant lymphoproliferative disease clinical trial
Current Status
Recruiting
Checked: October 15, 2026 at 5:51 PM UTC
| NCT Number | NCT03394365 |
| Recruiting Status | Recruiting |
| Condition | Post-transplant lymphoproliferative disease |
| Phase | PHASE3 |
| Target Enrollment | 115 participants |
| Active Locations | 40 sites in the US |
| Sponsor | Pierre Fabre Medicament |
| Last Updated on CT.gov | September 2, 2026 (Sep 2, 2026) |
As of October 15, 2026: Clinical trial NCT03394365 is currently recruiting participants. This phase3 study for post-transplant lymphoproliferative disease is actively seeking new participants at 40 locations across the United States. The study is sponsored by Pierre Fabre Medicament. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT03394365 is actively recruiting participants as of October 15, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 40 locations in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT03394365 was last updated Sep 2, 2026 (September 2, 2026). HelloStudys verifies this status automatically.